Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin.
Akagi
Tomoaki
T
Yamaguti
Kohei
K
Kawamura
Tizuko
T
Nakumura
Toshihiko
T
Kubo
Komei
K
Takemori
Hiromitu
H
D000368:Aged; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D054714:Echinocandins; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy*; D055666:Lipopeptides; D008074:Lipoproteins / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D000077551:Micafungin; D009181:Mycoses / Q000150:complications* / Q000209:etiology; D009504:Neutrophils / Q000166:cytology; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014250:Trichosporon / Q000378:metabolism*
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D000077551:Micafungin